bpc 157 human clinical trial tendon healing safety Ask anyone from gym bros to marathoners to your 65-year-old dad who says he's suddenly spry and you'll hear about BPC-157's potential to heal tendons and ligaments, speed up postsurgical recovery, and bpc-157 human evidence safety This

Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

This means it doesn't necessarily kill all bacteria, but it prevents them from growing and multiplying within the vial

Supporting Tissue Repair Inflammation often occurs when tissues become damaged

0.52, our pKaLearn models seemed to compete with previously reported models, which used this training/testing set design